Baseline monocyte and its classical subtype may predict efficacy of PD-1/PD-L1 inhibitor in cancers

Programmed death 1 (PD-1)/ programmed death-ligand 1 (PD-L1) inhibitor is one of the most popular immune therapies. Biomarkers for predicting response are highly needed, but no biomarkers are widely used till now. From February 2018 to April 2019, pan-cancer patients treated with PD-1 or PD-L1 inhib...

Full description

Saved in:

Bibliographic Details
Published in:	Bioscience reports 2021-01, Vol.41 (1)
Main Authors:	Shao, Yilin, Lin, Shuchen, Zhang, Ping, Zhang, Jian, Ji, Dongmei, Tao, Zhonghua, Hu, Xichun
Format:	Article
Language:	eng
Subjects:	Adult Aged Apoptosis B7-H1 Antigen - antagonists & inhibitors Biomarkers Blood Cancer Clinical trials Cloning Dose-Response Relationship, Drug Effectiveness Female Flow cytometry Humans Immune Checkpoint Inhibitors - administration & dosage Immune Checkpoint Inhibitors - therapeutic use Immunology & Inflammation Inhibitors Leukocytes (mononuclear) Ligands Male Medical tests Metastasis Middle Aged Monocytes Monocytes - classification Monocytes - immunology Multivariate analysis Neoplasms - drug therapy Neoplasms - immunology Patients PD-1 protein PD-L1 protein Peripheral blood mononuclear cells Pharmacology & Toxicology Programmed Cell Death 1 Receptor - antagonists & inhibitors Progression-Free Survival Software Statistical analysis Subgroups Tumors Young Adult
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	Programmed death 1 (PD-1)/ programmed death-ligand 1 (PD-L1) inhibitor is one of the most popular immune therapies. Biomarkers for predicting response are highly needed, but no biomarkers are widely used till now. From February 2018 to April 2019, pan-cancer patients treated with PD-1 or PD-L1 inhibitor as a single agent in our center were included. The benefit group included patients with partial response, complete response and stable disease, while the patients with progressive disease were classified into the nonbenefit group, according to the RECIST 1.1 criteria. Baseline peripheral blood was sampled to determine absolute monocyte count (AMC) and/or classical monocyte frequency (CMF) of peripheral blood mononuclear cells. Then, the association of the above-mentioned two biomarkers with response or progression-free survival (PFS) was evaluated. In total, 107 patients enrolled in the present study. The nonbenefit group had significantly larger number of AMC than benefit group (P
ISSN:	0144-8463 1573-4935